Epidemiology of Dementia: the MoVIES Project

Slides:



Advertisements
Similar presentations
Indianapolis Discovery Network for Dementia Comparative Effectiveness Research Trial of Alzheimers Disease Drug: COMET-AD.
Advertisements

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Supported by grants from: National Human Genome Research Institute (ELSI) HG/AG (The REVEAL Study); National Institute on Aging AG (The MIRAGE.
Designing Clinical Research Studies An overview S.F. O’Brien.
Epidemiological study of mild cognitive impairment and pilot evaluation of methods of early dementia detection in Chinese community Yueqin Huang MD MPH.
PRACTICE PARAMETER: RISK OF DRIVING AND ALZHEIMER ’ S DISEASE (AN EVIDENCE-BASED REVIEW) Richard M. Dubinsky, MD; Anthony C. Stein, PhD; and Kelly Lyons,
Neuropathology and Cognitive Scores Workgroup The role of vascular and Alzheimer’s Disease pathology in differential cognitive impairment among older adults.
Assessment/Enhancement of Cognitive Ability in Older Adults Karlene Ball Center for Research on Applied Gerontology University of Alabama at Birmingham.
Tony WAEGEMANS, MD UCB Pharma, Belgium. TW/ll/ Washington/MCI 2 MCI as implemented in our study MCI is a very early stage of dementia with as main.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Experimental Study.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Attrition and its effects – example from analysis of the MRC cognitive function and aging study Fiona Matthews MRC Biostatistics Unit.
ACTIVE Design Sites, Sampling, Replicates, and Follow-up.
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
Indianapolis Discovery Network for Dementia Comparative Effectiveness Research Trial of Alzheimer’s Disease Drugs: COMET-AD.
Epidemiology of Dementia: the MoVIES Project Alzheimer’s Disease Patient Registry (ADPR ), University of Pittsburgh Initially funded by NIA under.
CHP400: Community Health Program- lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Case Control Studies Present: Disease Past:
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
Procedures Manual, Control Series, & Phenotype Committee Update Stephanie Doan, MPH NIA AD Genetics Initiative Co-Coordinator Columbia University.
Why Physicians Do Not Diagnose Alzheimer’s Disease Mark A. Sager, MD Professor of Medicine and Population Health Sciences Director, Wisconsin Alzheimer’s.
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
MCI Conversion to Dementia: Clinic and Community-Based Studies
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
Case-Control Studies Abdualziz BinSaeed. Case-Control Studies Type of analytic study Unit of observation and analysis: Individual (not group)
Psychosis in Dementia Conclusions Psychosis in dementia is distressful and disturbing to patients and  Is similar across the spectrum of the dementia.
Mild Cognitive Impairment, Activity Participation, Functional Difficulty, and Adaptations in Functionally Vulnerable Elderly People: A Closer Look Laraine.
Copyright © 2008 Delmar. All rights reserved. Chapter 4 Epidemiology and Public Health Nursing.
DIABETES AS A RISK FACTOR FOR COGNITIVE DECLINE IN OLDER PATIENTS F. Limongi, A. Marseglia, S. Maggi, M. Noale, G. Romanato, P. Siviero, G. Crepaldi CNR,
Requirements to run clinical trials: Research fee calculation, patient consent Kyoung Hwa Ha.
Laura Baker, PhD Internal Medicine, Neurology, & Public Health Sciences Wake Forest School of Medicine Winston-Salem, NC USA.
Teguh Yudo Wicaksono*, Endra Dwi M*
Analytical Observational Studies
Aka STEEL VALLEY SENIORS SURVEY (SVSS)
M. M. Dumitru¹∙², V.Chirita¹∙², R.Chirita¹∙²
CERAD immediate memory verbal fluency (animals)
The behavioral pathology in Alzheimer's Disease Scale; BEHAVE-AD
REGARDS Overview George Howard, Virginia Wadley and Virginia (Ginny) Howard for the REGARDS investigators.
The BrainHealthRegistry
Falls and Fractures in Community Dwelling Elderly Cancer Survivors
Copyright © 2000 American Medical Association. All rights reserved.
Present: Disease Past: Exposure
Joe Verghese, MBBS, MS. Translating Insights from
Mayo Clinic College of Medicine
פסיכוגריאטריה ד''ר שורצמן בי''ח פלימן.
C-SCOPE: Survey on the Management of HCV in addiction clinics treating Patients on Opiate Agonist Therapies: a global perspective July 2017.
Dementia risk model validation in low and middle income countries
JAMA Ophthalmology Journal Club Slides: Validity of the Age-Related Eye Disease Study Grading Scale Vitale S, Clemons TE, Agrón E, et al; Age-Related Eye.
From the Indianapolis – Ibadan Dementia Research Project.
Li-Yu Tang1, Ta-Fu Chen1,2, Ming-Jang Chiu1,2*
Evaluating the cost-effectiveness of interventions with an impact on ageing P. Breeze, P. Thokala, L. Lafortune, C. Brayne, A. Brennan 07/12/2018.
ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue
Does Multilingualism Protect Against Alzheimer’s Disease
BMTRY 738: The Study Population
Epidemiology MPH 531 Analytic Epidemiology Case control studies
Excessive Daytime Sleepiness & Depression
NIH’S Redefinition of Clinical Trials and Using the New Human Subjects Form Chris Sylvester, M.A. Senior Grant Administrator (AO) Grants and Contracts.
The Cardiovascular Health Study:
M Javanbakht, S Guerry, LV Smith, P Kerndt
HEC508 Applied Epidemiology
WS2.1 Update.
Decision-Making Capacity - under the medical model
SYNOPSIS OF THE PROTOCOL
NAACCR/IACR Annual Conference, June 2019
Presentation transcript:

Epidemiology of Dementia: the MoVIES Project Alzheimer’s Disease Patient Registry (ADPR ), University of Pittsburgh Initially funded by NIA 1987-1989 under cooperative agreement, U01 AG06782: Population-based Dementia Registry: Subsequently funded by NIA 1989-2002 as project grant R01, AG07562, Epidemiology of Dementia: A Prospective Community Study. Locally called “Monongahela Valley Independent Elders Survey” (MoVIES). Home

MoVIES Project Site: mid- Monongahela Valley in Washington and Westmoreland counties, Southwestern Pennsylvania; 23 communities served by the 23 Mon Valley communities served by the Mon Valley Community Health Center, Monessen, PA. Rural area with small towns, former home to coal mines and steel mills until the 1970s. Home

MoVIES Cohort Random sample, N=1422 1:13 age-stratified (65-74, 75+ years) random sample drawn from Voter Registration lists for the selected communities. Volunteer sample, N=259 drawn from same area, meeting same entry criteria. Home

MoVIES Entry Criteria Age 65+ at time of recruitment; Mon Valley resident; Not in nursing home at time of recruitment; Fluent in English; At least Grade 6 education. Home

MoVIES Cohort Characteristics Total sample size of original cohort: N=1681 (random plus volunteer) Age: Mean (SD) = 72.6 (5.7) yrs (baseline) Sex ratio: F:M=55.5 : 45 Education: % < high school graduate: 43.3% Home

MoVIES:Overview Sample recruited 1987-1989 as part of ADPR; prevalent cases identified. Began prospective followup in 1989; Subjects re-assessed approximately every two years; incident cases identified. Followup completed in 2002. Home

MoVIES Screening Cognitive Tests MMSE CERAD Word List (10) Learning (3 trials) Delayed Recall Delayed Recognition (originals and foils) Story Immediate Recall Boston Naming (15) Word Fluency P&S Fruits & Animals CERAD Praxis (4) Clock Drawing Trailmaking A Trailmaking B Temporal Orientation Home

MoVIES:Study procedures At each wave: All consenting survivors: cognitive screening and risk factor assessment. Screening identifies those who are (a) cognitively “impaired;” (b) cognitively “declined.” Impaired and declined subjects undergo clinical diagnostic evaluation for dementia. Home

MoVIES Screening Criteria (1) Cognitive impairment: Actual scores, at any given time, at or below the 10th %ile of the sample on: MMSE and/or At least one memory test and one other test. Home

MoVIES Screening Criteria (2) Cognitive Decline: Decline over time in scores To “impaired” levels, and/or By amounts greater than or equal to that experienced by 95 % of the cohort on MMSE and/or At least two other tests. Home

MoVIES Clinical Evaluation (1) In-home evaluation; History and general physical exam; Detailed neurological exam; Brief mental status exam; Psychiatric exam; Blood: chemistry/hematology/serology; Home

MoVIES Clinical Evaluation (2) Based on Pittsburgh ADRC/CERAD assessment protocols, modified for field use; DSM-III-R criteria for dementia; CDR rating for stage/severity; NINCDS-ADRDA criteria for Probable and Possible AD. Home